An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

This open-label, rater-blinded extension study enrolled participants who had
relapsing-remitting multiple sclerosis (RRMS) and who participated in one of three prior
Genzyme-sponsored studies of alemtuzumab (CAMMS223 [NCT00050778], CAMMS323 [NCT00530348] also
known as CARE-MS I, or CAMMS324 [NCT00548405] also known as CARE-MS II). The purposes of this
study were:

1. To examine the long term safety and efficacy of alemtuzumab treatment in participants
who received alemtuzumab as their study treatment in one of the prior studies.

2. To examine the safety and efficacy of initial alemtuzumab treatment in this study for
participants who received Rebif® (interferon beta-1a) as their study treatment in one of
the prior studies.

3. To determine the safety and efficacy of additional "as needed" alemtuzumab treatment
courses. This applied both to participants who received alemtuzumab for the first time
in one of the prior studies or for the first time in this extension study.